To investigate the predictive values of the serum chemokine ligand 11 (CCL11) and interleukin-13 (IL-13) levels of pregnant women with gestational diabetes mellitus (GDM) for their risk of preeclampsia (PE). Methods: The clinical data of 144 pregnant women with GDM admitted to the hospital from September 2021 to August 2023 were selected as the subjects of this study. According to the occurrence of preeclampsia or not, these women were divided into group A (52 women with GDM complicated with PE) and group B (92 women with GDM only). In addition, 120 normal pregnant women were selected in group C during the same period. The levels of serum CCL11 and IL-13 of the women were compared among the three groups. The predictive value of the serum CCL11 and IL-13 levels of the women with GDM for their PE was evaluated by receiver operator characteristic (ROC) curve. The factors influencing the occurrence of PE of the women with GDM were investigated by binary logistic step by step regression analysis. Results: The serum CCL11 level of the women in group A (77.98±8.35 pg/ml), in group B (44.69±5.13 pg/ml) and in group C (25.73±4.05 pg/ml) had decreased gradually. The serum level of IL-13 of the women in group A (12.43±2.84 pg/ml), in group B (18.23±3.37 pg/ml) and in group C (27.42±4.14 pg/ml) had increased gradually (all P<0.05). The area under the curve (AUC) of the serum CCL11 level, the IL-13 level and the combination of the serum CCL11 and IL-13 levels of the women with GDM for predicting their PE were 0.768, 0.853 and 0.911, respectively, the specificity of which were 56.1%, 65.6% and 86.4%, respectively, and the sensitivity of which were 90.7%, 90.7% and 84.5%, respectively. Regression analysis showed that the high pre-pregnancy BMI (OR=2.073), the high HOMA-IR values (OR=2.333), the CCL11 level ≥61.10pg/ml (OR=2.697), and the IL-13 level ≤15.31pg/ml (OR=0.299) of the women with GDM were the independent risk factors of their PE occurrence (all P<0.05). Conclusion: The high expression of the CCL11 and the low expression of IL-13 of the women with GDM are associated with their PE occurrence, and both of which can be used as the biomarkers for predicting the risk of their PE occurrence.